{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:00:19Z","timestamp":1784865619104,"version":"3.55.0"},"reference-count":64,"publisher":"Oxford University Press (OUP)","issue":"16","license":[{"start":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:00:00Z","timestamp":1649116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Oral antiplatelet therapy is routinely used to prevent adverse cardiovascular events in patients with peripheral artery disease (PAD). Several laboratory tests are available to quantify the degree of platelet inhibition following antiplatelet therapy. This article aims to provide a review of the literature surrounding platelet functional testing in patients with PAD receiving oral P2Y12 inhibitors and to offer guidance to clinicians for the use and interpretation of these tests.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>A literature search of PubMed and the Web of Science Core Collection database was conducted. All studies that performed platelet function testing and reported clinical outcomes in patients with PAD were included. Evaluation of the data suggests that, among the available testing strategies, the VerifyNow platelet reactivity unit (PRU) test is the most widely used. Despite numerous investigations attempting to define a laboratory threshold indicating suboptimal response to antiplatelet therapy, controversy exists about which PRU value best correlates with cardiovascular outcomes (ie, mortality, stent thrombosis, etc). In the PAD literature, the most commonly used PRU thresholds are 208 or higher and 235 or higher. Nonetheless, adjusting antiplatelet regimens based on suboptimal P2Y12 reactivity values has yet to be proven useful in reducing the incidence of adverse cardiovascular outcomes. This review examines platelet function testing in patients with PAD and discusses the interpretation and application of these tests when monitoring the safety and efficacy of P2Y12 inhibitors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Although platelet functional tests may be simple to use, clinical trials thus far have failed to show benefit from therapy adjustments based on test results. Clinicians should be cautioned against relying on this test result alone and should instead consider a combination of laboratory, clinical, and patient-specific factors when adjusting P2Y12 inhibitor therapy in clinical practice.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxac095","type":"journal-article","created":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T20:12:05Z","timestamp":1649189525000},"page":"1312-1322","source":"Crossref","is-referenced-by-count":3,"title":["Platelet reactivity testing in peripheral artery disease"],"prefix":"10.1093","volume":"79","author":[{"given":"Youqi","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Oregon Health & Science University , Portland, OR , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer W","family":"Chou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, UC San Diego Health , La Jolla, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Ting","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, UC San Diego Health , La Jolla, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Derry","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, UC San Diego Health , La Jolla, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doug","family":"Humber","sequence":"additional","affiliation":[{"name":"Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California , San Diego, La Jolla, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,4,5]]},"reference":[{"issue":"6921","key":"2022080508592893300_CIT0001","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Collaborative overview of randomised trials of antiplatelet therapy\u2014I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients","volume":"308","author":"Antiplatelet Trialists\u2019 Collaboration","year":"1994","journal-title":"BMJ."},{"issue":"7329","key":"2022080508592893300_CIT0002","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","author":"Antithrombotic Trialists\u2019 Collaboration","year":"2002","journal-title":"BMJ."},{"issue":"11","key":"2022080508592893300_CIT0003","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/j.jacc.2016.11.007","article-title":"2016 AHA\/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"69","author":"Gerhard-Herman","year":"2017","journal-title":"J Am Coll Cardiol."},{"issue":"3 suppl","key":"2022080508592893300_CIT0004","doi-asserted-by":"crossref","first-page":"1S","DOI":"10.1016\/j.jvs.2014.12.006","article-title":"Society for Vascular Surgery Practice guidelines for atherosclerotic occlusive disease of the lower extremities management of asymptomatic disease and claudication. Introduction","volume":"61","author":"Conte","year":"2015","journal-title":"J Vasc Surg."},{"issue":"2","key":"2022080508592893300_CIT0005","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/eurheartj\/ehn534","article-title":"Patients with peripheral arterial disease in the CHARISMA trial","volume":"30","author":"Cacoub","year":"2009","journal-title":"Eur Heart J."},{"issue":"6","key":"2022080508592893300_CIT0006","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1177\/2047487314533215","article-title":"Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: data from the PLATO Trial","volume":"22","author":"Patel","year":"2015","journal-title":"Eur J Prev Cardiol."},{"issue":"12","key":"2022080508592893300_CIT0007","doi-asserted-by":"crossref","first-page":"912","DOI":"10.4330\/wjc.v7.i12.912","article-title":"Current status of high on-treatment platelet reactivity in patients with coronary or peripheral arterial disease: mechanisms, evaluation and clinical implications","volume":"7","author":"Spiliopoulos","year":"2015","journal-title":"World J Cardiol."},{"issue":"10055","key":"2022080508592893300_CIT0008","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(16)31323-X","article-title":"Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial","volume":"388","author":"Cayla","year":"2016","journal-title":"Lancet."},{"issue":"8","key":"2022080508592893300_CIT0009","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.2020.12443","article-title":"Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial","volume":"324","author":"Pereira","year":"2020","journal-title":"JAMA."},{"issue":"24","key":"2022080508592893300_CIT0010","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.jacc.2011.08.007","article-title":"A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions","volume":"58","author":"Levine","year":"2011","journal-title":"J Am Coll Cardiol."},{"issue":"24","key":"2022080508592893300_CIT0011","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 AHA\/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"64","author":"Amsterdam","year":"2014","journal-title":"J Am Coll Cardiol."},{"issue":"9","key":"2022080508592893300_CIT0012","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","article-title":"2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries","volume":"39","author":"Aboyans","year":"2018","journal-title":"Eur Heart J."},{"issue":"6","key":"2022080508592893300_CIT0013","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/0002-9149(79)90154-1","article-title":"Role of blood platelets in coronary artery disease","volume":"43","author":"Haft","year":"1979","journal-title":"Am J Cardiol."},{"issue":"8","key":"2022080508592893300_CIT0014","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/MCA.0000000000000178","article-title":"Endothelial dysfunction and coronary artery disease: assessment, prognosis, and treatment","volume":"25","author":"Matsuzawa","year":"2014","journal-title":"Coron Artery Dis."},{"issue":"1","key":"2022080508592893300_CIT0015","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1053\/ejvs.2002.1795","article-title":"The role of platelets in peripheral vascular disease","volume":"25","author":"Cassar","year":"2003","journal-title":"Eur J Vasc Endovasc Surg."},{"issue":"2","key":"2022080508592893300_CIT0016","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s10016-001-0159-8","article-title":"The role of platelets in peripheral arterial disease: therapeutic implications","volume":"16","author":"Matsagas","year":"2002","journal-title":"Ann Vasc Surg."},{"issue":"12","key":"2022080508592893300_CIT0017","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1172\/JCI27196","article-title":"Platelets in inflammation and atherogenesis","volume":"115","author":"Gawaz","year":"2005","journal-title":"J Clin Invest."},{"issue":"3","key":"2022080508592893300_CIT0018","doi-asserted-by":"crossref","first-page":"s5","DOI":"10.1161\/ATVBAHA.107.158915","article-title":"Platelets: inflammatory firebugs of vascular walls","volume":"28","author":"May","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"16","key":"2022080508592893300_CIT0019","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1093\/eurheartj\/ehp296","article-title":"P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use","volume":"30","author":"Wallentin","year":"2009","journal-title":"Eur Heart J."},{"key":"2022080508592893300_CIT0020","volume-title":"Clopidogrel. Package insert","year":"2010"},{"issue":"8","key":"2022080508592893300_CIT0021","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA."},{"issue":"9","key":"2022080508592893300_CIT0022","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1097\/CM9.0000000000000210","article-title":"Clinical outcomes and predictive model of platelet reactivity to clopidogrel after acute ischemic vascular events","volume":"132","author":"Ma","year":"2019","journal-title":"Chin Med J."},{"issue":"9","key":"2022080508592893300_CIT0023","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1007\/s00330-012-2441-2","article-title":"Management of peripheral arterial interventions with mono or dual antiplatelet therapy\u2014the MIRROR study: a randomised and double-blinded clinical trial","volume":"22","author":"Tepe","year":"2012","journal-title":"Eur Radiol."},{"key":"2022080508592893300_CIT0024","author":"Food and Drug Administration"},{"issue":"16","key":"2022080508592893300_CIT0025","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.jcin.2019.03.034","article-title":"Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention","volume":"12","author":"Sibbing","year":"2019","journal-title":"JACC Cardiovasc Interv."},{"issue":"10A","key":"2022080508592893300_CIT0026","doi-asserted-by":"crossref","first-page":"4N","DOI":"10.1016\/j.amjcard.2006.09.008","article-title":"Current options in platelet function testing","volume":"98","author":"Michelson","year":"2006","journal-title":"Am J Cardiol."},{"issue":"8","key":"2022080508592893300_CIT0027","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.3390\/jcm9082636","article-title":"Advances in platelet function testing\u2014light transmission aggregometry and beyond","volume":"9","author":"Le Blanc","year":"2020","journal-title":"J Clin Med."},{"key":"2022080508592893300_CIT0028","doi-asserted-by":"crossref","DOI":"10.1182\/hem.V11.2.2555","article-title":"Ask the hematologist: light transmission aggregometry","author":"Cuker","year":"2014","journal-title":"The Hematologist."},{"issue":"1","key":"2022080508592893300_CIT0029","doi-asserted-by":"crossref","first-page":"9955","DOI":"10.1038\/s41598-018-28181-8","article-title":"Vasodilator-stimulated phosphoprotein (VASP) is not a major mediator of platelet aggregation, thrombogenesis, haemostasis, and antiplatelet effect of prasugrel in rats","volume":"8","author":"Ito","year":"2018","journal-title":"Sci Rep."},{"issue":"1","key":"2022080508592893300_CIT0030","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1538-7836.2004.01063.x","article-title":"Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases","volume":"3","author":"Aleil","year":"2005","journal-title":"J Thromb Haemost."},{"issue":"1","key":"2022080508592893300_CIT0031","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3343\/alm.2019.39.1.23","article-title":"Effectiveness of Platelet Function Analyzer-100 for laboratory detection of anti-platelet drug-induced platelet dysfunction","volume":"39","author":"Kweon","year":"2019","journal-title":"Ann Lab Med."},{"issue":"4","key":"2022080508592893300_CIT0032","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/ajh.24620","article-title":"Clinical utility of closure times using the Platelet Function Analyzer-100\/200","volume":"92","author":"Favaloro","year":"2017","journal-title":"Am J Hematol."},{"issue":"5","key":"2022080508592893300_CIT0033","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1365-2141.2005.05680.x","article-title":"Variables influencing Platelet Function Analyzer-100 closure times in healthy individuals","volume":"130","author":"Haubelt","year":"2005","journal-title":"Br J Haematol."},{"key":"2022080508592893300_CIT0034","author":"Food"},{"key":"2022080508592893300_CIT0035","author":"Food and Drug Administration"},{"issue":"6","key":"2022080508592893300_CIT0036","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.ejvs.2011.08.014","article-title":"On-treatment function testing of platelets and long-term outcome of patients with peripheral arterial disease undergoing transluminal angioplasty","volume":"42","author":"van der Loo","year":"2011","journal-title":"Eur J Vasc Endovasc Surg."},{"issue":"4","key":"2022080508592893300_CIT0037","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ejvs.2018.06.032","article-title":"On-treatment platelet reactivity is a predictor of adverse events in peripheral artery disease patients undergoing percutaneous angioplasty","volume":"56","author":"Grifoni","year":"2018","journal-title":"Eur J Vasc Endovasc Surg."},{"issue":"4","key":"2022080508592893300_CIT0038","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1159\/000489970","article-title":"Role of dipyrone in the high on-treatment platelet reactivity amongst acetylsalicylic acid-treated patients undergoing peripheral artery revascularisation","volume":"27","author":"Hartinger","year":"2018","journal-title":"Med Princ Pract."},{"issue":"11","key":"2022080508592893300_CIT0039","doi-asserted-by":"crossref","first-page":"871","DOI":"10.3390\/diagnostics10110871","article-title":"Personalization of aspirin therapy ex vivo in patients with atherosclerosis using light transmission aggregometry","volume":"10","author":"Khan","year":"2020","journal-title":"Diagnostics."},{"issue":"3","key":"2022080508592893300_CIT0040","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/09537104.2020.1742314","article-title":"Impact of high on-treatment platelet reactivity after angioplasty in patients with peripheral arterial disease","volume":"32","author":"Busch","year":"2021","journal-title":"Platelets."},{"issue":"10","key":"2022080508592893300_CIT0041","first-page":"1601","article-title":"Response to dual antiplatelet therapy in patients with peripheral artery occlusive disease suffering from critical limb ischemia","volume":"60","author":"Wand","year":"2014","journal-title":"Clin Lab."},{"issue":"12","key":"2022080508592893300_CIT0042","doi-asserted-by":"crossref","first-page":"e0244330","DOI":"10.1371\/journal.pone.0244330","article-title":"Perioperative changes of response to antiplatelet medication in vascular surgery patients","volume":"15","author":"Hummel","year":"2020","journal-title":"PLoS One."},{"issue":"1","key":"2022080508592893300_CIT0043","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3390\/diagnostics11010143","article-title":"Viscoelastic hemostatic assays and platelet function testing in patients with atherosclerotic vascular diseases","volume":"11","author":"Samos","year":"2021","journal-title":"Diagnostics."},{"issue":"3","key":"2022080508592893300_CIT0044","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.thromres.2006.01.019","article-title":"Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12 rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study","volume":"119","author":"Malinin","year":"2007","journal-title":"Thromb Res."},{"issue":"24","key":"2022080508592893300_CIT0045","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1016\/j.jacc.2013.03.036","article-title":"Platelet responsiveness to clopidogrel treatment after peripheral endovascular procedures: the PRECLOP study: clinical impact and optimal cutoff value of on-treatment high platelet reactivity","volume":"61","author":"Spiliopoulos","year":"2013","journal-title":"J Am Coll Cardiol."},{"issue":"4","key":"2022080508592893300_CIT0046","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1007\/s00330-014-3487-0","article-title":"Disadvantages of using the area under the receiver operating characteristic curve to assess imaging tests: a discussion and proposal to an alternative approach","volume":"25","author":"Halligan","year":"2015","journal-title":"Eur Radiol."},{"issue":"7","key":"2022080508592893300_CIT0047","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1002\/ccd.27453","article-title":"Aspirin and clopidogrel high on-treatment platelet reactivity and genetic predictors in peripheral arterial disease","volume":"91","author":"Yeo","year":"2018","journal-title":"Catheter Cardiovasc Interv."},{"issue":"3","key":"2022080508592893300_CIT0048","doi-asserted-by":"crossref","first-page":"e004904","DOI":"10.1161\/CIRCINTERVENTIONS.116.004904","article-title":"Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents in subjects with peripheral arterial disease: analysis from the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents)","volume":"10","author":"Gupta","year":"2017","journal-title":"Circ Cardiovasc Interv."},{"issue":"9892","key":"2022080508592893300_CIT0049","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","article-title":"Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study","volume":"382","author":"Stone","year":"2013","journal-title":"Lancet."},{"issue":"17","key":"2022080508592893300_CIT0050","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation."},{"issue":"6","key":"2022080508592893300_CIT0051","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/joic.12251","article-title":"Low on-treatment platelet reactivity predicts long-term risk of bleeding after elective PCI","volume":"28","author":"Colic","year":"2015","journal-title":"J Interv Cardiol."},{"issue":"11","key":"2022080508592893300_CIT0052","doi-asserted-by":"crossref","first-page":"e003977","DOI":"10.1161\/JAHA.116.003977","article-title":"Relationship of platelet reactivity with bleeding outcomes during long-term treatment with dual antiplatelet therapy for medically managed patients with non-ST-segment elevation acute coronary syndromes","volume":"5","author":"Cornel","year":"2016","journal-title":"J Am Heart Assoc."},{"issue":"10","key":"2022080508592893300_CIT0053","doi-asserted-by":"crossref","first-page":"e015439","DOI":"10.1161\/JAHA.119.015439","article-title":"Relationship between platelet reactivity and ischemic and bleeding events after percutaneous coronary intervention in East Asian patients: 1-year results of the PENDULUM Registry","volume":"9","author":"Nakamura","year":"2020","journal-title":"J Am Heart Assoc."},{"issue":"2","key":"2022080508592893300_CIT0054","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejvs.2016.04.019","article-title":"High on-treatment platelet reactivity in peripheral arterial disease: a pilot study to find the optimal test and cut off values","volume":"52","author":"Leunissen","year":"2016","journal-title":"Eur J Vasc Endovasc Surg."},{"issue":"5 Pt A","key":"2022080508592893300_CIT0055","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.carrev.2017.10.013","article-title":"Prevalence of high on-treatment (aspirin and clopidogrel) platelet reactivity in patients with critical limb ischemia","volume":"19","author":"Clavijo","year":"2018","journal-title":"Cardiovasc Revasc Med."},{"issue":"11","key":"2022080508592893300_CIT0056","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.2011.290","article-title":"Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial","volume":"305","author":"Price","year":"2011","journal-title":"JAMA."},{"issue":"24","key":"2022080508592893300_CIT0057","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","article-title":"A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study","volume":"59","author":"Trenk","year":"2012","journal-title":"J Am Coll Cardiol."},{"issue":"18","key":"2022080508592893300_CIT0058","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.jacc.2010.03.103","article-title":"Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T\/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and\/or resistance to clopidogrel) trial substudy","volume":"56","author":"Campo","year":"2010","journal-title":"J Am Coll Cardiol."},{"issue":"1","key":"2022080508592893300_CIT0059","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1611688","article-title":"Ticagrelor versus clopidogrel in symptomatic peripheral artery disease","volume":"376","author":"Hiatt","year":"2017","journal-title":"N Engl J Med."},{"issue":"11","key":"2022080508592893300_CIT0060","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med."},{"issue":"21","key":"2022080508592893300_CIT0061","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N Engl J Med."},{"issue":"10117","key":"2022080508592893300_CIT0062","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","article-title":"Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Anand","year":"2018","journal-title":"Lancet."},{"issue":"2","key":"2022080508592893300_CIT0063","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1538-7836.2009.03699.x","article-title":"Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay","volume":"8","author":"Siller-Matula","year":"2010","journal-title":"J Thromb Haemost."},{"issue":"7","key":"2022080508592893300_CIT0064","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/09537100802317918","article-title":"The use of the VerifyNow system to monitor antiplatelet therapy: a review of the current evidence","volume":"19","author":"van Werkum","year":"2008","journal-title":"Platelets."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxac095\/43556563\/zxac095.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/79\/16\/1312\/45232807\/zxac095.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/79\/16\/1312\/45232807\/zxac095.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T09:01:01Z","timestamp":1659690061000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/79\/16\/1312\/6563940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,5]]},"references-count":64,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2022,4,5]]},"published-print":{"date-parts":[[2022,8,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxac095","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8,15]]},"published":{"date-parts":[[2022,4,5]]}}}